Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Three month outcomes for SMILE between -9.00 and -14.00 D

Search Title by author or title

Session Details

Session Title: Small Lenticule Extraction

Session Date/Time: Tuesday 25/09/2018 | 08:00-10:30

Paper Time: 08:06

Venue: Room A3, Podium 3

First Author: : R.Vida UK

Co Author(s): :    D. Reinstein   G. Carp   T. Archer              

Abstract Details


To report the outcomes of SMILE for high myopia between -9.00 and -14.00 D.


London Vision Clinic, London, UK


This was a prospective study ( identifier: NCT02528123) of SMILE for high myopia using the VisuMax femtosecond laser (Carl Zeiss Meditec). Inclusion criteria were attempted spherical equivalent refraction between -9.00 and -14.00 D, cylinder up to 7.00 D, CDVA 20/40 or better, age 21 years or older, and suitable for SMILE. The sub-lenticule thickness was ≥220 µm, and the total uncut stromal thickness was ≥300 µm. Patients will be followed for 1 year. At the time of writing 3 month data were available. Standard outcomes analysis was performed.


To date, 69 eyes (43 patients) have been recruited. Mean attempted SEQ was -10.55±1.06 D (-9.01 to -12.99 D). Mean cylinder was -1.10±0.76 D (0.00 to -3.50 D). Preop CDVA was 20/20 or better in 70% of eyes. Postop UDVA was 20/20 or better in 53% and 20/25 or better in 82% of eyes. Mean postop SEQ relative to the target was -0.20±0.52 D (-1.29 to +1.50 D), with 68% within ±0.50 D. There was 1 line loss CDVA in 7% of eyes, and no eyes lost 2 or more lines CDVA. Contrast sensitivity was unchanged.


Three month outcomes of SMILE for myopia above -9.00 D show excellent efficacy, safety, and predictability. Further follow-up is required to evaluate refractive and corneal stability, as well as quality of vision and aberration induction.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous